関: medroxyprogesterone 17-acetate、medroxyprogesterone acetate

WordNet

a progestin compound (trade name Provera) used to treat menstrual disorders (同)Provera

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/11/07 02:24:45」(JST)

wiki en

This article is about a non-clinically used progestin compound. For the pharmaceutical drug, see medroxyprogesterone acetate.

Medroxyprogesterone (INN, BAN), also known as 17α-hydroxy-6α-methylprogesterone, and abbreviated as MP, is a steroidal progestin drug which was never marketed for use in humans.^[1] An acylated derivative, medroxyprogesterone acetate (MPA), is clinically used as a pharmaceutical medicine.^[2] Compared to MPA, MP is over two orders of magnitude less potent as a progestogen.^[3] As such, MP itself is not used clinically, though it has seen limited use in veterinary medicine under the trade name Controlestril in France.^[4] In addition, it is an metabolite of MPA.^[5]

While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate,^[2] what is normally being administered is MPA and not MP.^[6]

References[edit]

^ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1079. ISBN 978-0-412-46630-4. Retrieved 28 May 2012.
^ ^a ^b "MedroxyPROGESTERone: Drug Information Provided by Lexi-Comp". Merck Manual. 2009-12-01. Retrieved 2010-07-08.
^ Pullen MA, Laping N, Edwards R, Bray J (September 2006). "Determination of conformational changes in the progesterone receptor using ELISA-like assays". Steroids 71 (9): 792–8. doi:10.1016/j.steroids.2006.05.009. PMID 16784762.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 638. ISBN 978-3-88763-075-1. Retrieved 28 May 2012.
^ Ishihara M, Kirdani Y, Osawa Y, Sandberg AA (January 1976). "The metabolic fate of medroxyprogesterone acetate in the baboon". J. Steroid Biochem. 7 (1): 65–70. doi:10.1016/0022-4731(76)90167-9. PMID 1271819.
^ Lenco W, Mcknight M, Macdonald AS (January 1975). "Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits". Ann. Surg. 181 (1): 67–73. doi:10.1097/00000658-197501000-00015. PMC 1343717. PMID 1119869.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 避妊のための酢酸メドロキシプロゲステロンデポ剤 depot medroxyprogesterone acetate for contraception
2. 子宮内膜増殖症のマネージメント management of endometrial hyperplasia
3. 避妊している女性におけるホルモン剤内服中の出血のマネージメント management of unscheduled bleeding in women using contraception
4. 閉経後のホルモン療法で用いる製剤 preparations for postmenopausal hormone therapy
5. 子宮内膜間質腫瘍の分類および治療 classification and treatment of endometrial stromal tumors

English Journal

Postmenopausal hormone use impact on emotion processing circuitry.

Shafir T, Love T, Berent-Spillson A, Persad CC, Wang H, Reame NK, Frey KA, Zubieta JK, Smith YR.SourceMolecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, United States.
Behavioural brain research.Behav Brain Res.2012 Jan 1;226(1):147-53. Epub 2011 Sep 14.
Despite considerable evidence for potential effects of estrogen on emotional processing, several studies of postmenopausal women who began hormone therapy (HT) remote from menopause report no effects of HT on emotional measures. As early HT initiation may preserve brain mechanisms, we examined effec
PMID 21930160

Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.

Segall-Gutierrez P, Xiang AH, Watanabe RM, Trigo E, Stanczyk FZ, Liu X, Jurow R, Buchanan TA.SourceDepartment of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Contraception.Contraception.2012 Jan;85(1):36-41. Epub 2011 Jun 11.
BACKGROUND: Highly effective contraception is essential in obese women, but it should not increase their risk of developing or worsening obesity-related cardiometabolic illness. The purpose of this 18-week prospective experimental study was to compare the impact of subcutaneous depot medroxyprogeste
PMID 22067800

Japanese Journal

妊孕能温存治療後に再発を認めた低悪性度子宮内膜間質肉腫の2症例

坂根理矢,鍔本浩志,池田ゆうき,井上佳代,金澤理一郎,小森慎二,羽尾裕之,廣田誠一
産婦人科の進歩 63(2), 99-105, 2011
… が施行された2症例について，その後の転機を含めて報告する．【症例1】26歳時，子宮筋腫の診断で前医にて腹腔鏡下筋腫核出術が施行され，摘出標本にてLGESSと診断された．未経産で強い挙児希望のためmedroxyprogesterone acetate (MPA) 投与にて経過観察され， 32歳時（術後81ヵ月）当科へ紹介となった．超音波検査およびMRI検査にて子宮体下部左側の再発と左基靭帯への浸潤が疑われた．18F-fluorodeoxygrucose（18-FDG）PET検査では …
NAID 130000904750

(3)子宮体癌における高単位プロゲステロンによる妊孕性温存療法 : 治療効果および安全性,その後の妊娠について,長期観察結果(<特集>第62回学術講演会シンポジウム1 婦人科癌における妊孕性温存治療(手術および薬物療法))

牛嶋公生
日本産科婦人科學會雜誌 62(10), 2107-2114, 2010-10-01
… To clarify the efficacy of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC) and atypical hyperplasia (AH) in young women, we conducted multicenter prospective study for this issue at 16 institutions in Japan. …
NAID 110007730377

Related Pictures

★リンクテーブル★

リンク元	「メドロキシプロゲステロン」
拡張検索	「medroxyprogesterone 17-acetate」「medroxyprogesterone acetate」

「メドロキシプロゲステロン」

Medroxyprogesterone
Systematic (IUPAC) name
	(6α)-17-hydroxy-6-methylpregn-4-ene-3,20-dione
Clinical data
Pregnancy cat.	X
Legal status	?
Identifiers
CAS number	520-85-4
ATC code	None
PubChem	CID 1063110631
ChemSpider	10185
Chemical data
Formula	C22H32O3
Mol. mass	344.488 g/mol
	SMILES O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@@H]2C)C)(C)CC4;
	InChI InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1; Key:FRQMUZJSZHZSGN-HBNHAYAOSA-N ;